Effect of Preoperative Curcumin in Breast Cancer Patients (EPC)

University of Malaya

Status: Unknown

Conditions: Breast Cancer

Treatments: Other: Placebo; Dietary Supplement: Curcumin

Study type: Interventional

Funder types: Other

Identifiers

NCT03847623

20149-582

Details and patient eligibility

About

Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative patients

Full description

Patients diagnosed with breast cancer will be supplemented with either curcumin or placebo for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.

Enrollment: 30 estimated patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with operable breast cancer
• Life expectancy of at least 3 months
• Adequate organ function
• No allergy to curcumin
• Provides consent to participate in trial and adhere to the study protocol

Exclusion criteria

• Receiving concomitant radiotherapy, hormonal, immune therapy or other investigational drugs
• Uncontrolled concurrent illness
• Patient of anti platelet medications
• Pregnant / breast feeding
• Patients who are unable or unwilling to take curcumin, herbal remedies, or non-prescription medications
• Patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting profile

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

30 participants in 2 patient groups, including a placebo group

Curcumin

Experimental group

Description:

Capsules, taken orally, 8g per day (Bi-daily dosing)

Treatment:

Dietary Supplement: Curcumin

Placebo

Placebo Comparator group

Description:

Capsules, taken orally, bi-daily dosing

Treatment:

Other: Placebo